Search results
How Does Psoriasis Affect Pregnancy?
Verywell Health via Yahoo News· 6 days agoExperiencing psoriasis during pregnancy is unlikely to pose a risk for your fetus, but it can affect each person differently. Here’s what you need to...
Two Biosimilars Approved in Europe for Autoimmune Disorders
Medscape· 5 days agoThe drugs are intended to treat several types of arthritis, psoriasis, COVID-19, and Crohn's...
Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer
Morningstar· 7 days agoOruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including ...
These Pictures Will Help You Identify the Most Common Skin Rashes
Prevention via Yahoo News· 5 days agoFrom eczema to allergic reactions to bug bites, here’s what common skin rashes look like in photos,...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx...
Morningstar· 3 days agoPomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) and certain officers. The class action, filed in ...
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 6 days agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 8 hours agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares fell 0.5% on Monday after Barclays lowered their price target on the stock from $195.00 to $187.00. AbbVie traded as low as $158.56 and last ...
AbbVie's newer drugs are offsetting losses of the world's once best-selling medication
Quartz· 5 days agoSales of the pharma giant's newer drugs are offsetting its Humira losses.
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 1 day agoAbbVie (NYSE:ABBV – Free Report) had its price objective cut by BMO Capital Markets from $195.00 to $180.00 in a report published on Monday morning, Benzinga reports. A number of other analysts ...
AbbVie (ABBV) to Release Quarterly Earnings on Friday
ETF DAILY NEWS· 6 days agoAbbVie (NYSE:ABBV – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, April 26th. Analysts expect the company to announce earnings of ...
